Below is a list of the clinical trials our practice has been affiliated with, and we are always considering new trials. Please contact our study coordinator for the most up-to-date enrollment status on studies.
Alcon, Principal Investigator, Post Approval Study of the AcrySof® IQ Toric High Cylinder Power IOL Models SN6AT6-SN6AT9, 2012.
Case Western Reserve University, Effect of Corneal Preservation Time on Long-Term Graft Success Cornea Preservation Time Study (CPTS), 2012.
Alcon, Long Term Safety Protocol for AcrySof® Cachet™ Phakic Lens, 2011.
Alcon, A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome, 2011
Alcon, Evaluation of FID 114657 in Dry Eye Subjects with Sjogren’s Syndrome (SMA-09-65), 2010.
Inspire Pharmaceuticals, 03-113: A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of diquafosol tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale), 2009.
Alcon, “Assessement of inflammatory biomarkers in a non-Sjogren’s severe dry eye population” (JADE 3), 2008.
Alcon, “Assessment of Inflammatory Biomarkers Expressed in a Sjögren’s Population: Effect of Maxidex Intervention” (JADE2), 2008.
Alcon, “AcrySof Small Incision, Angle-Supported Phakic IOL for the Treatment of High Myopia.”
LUX Biosciences, Phase III, LX201-01: Study to Assess LX201 for Prevention of Corneal Graft Rejection and Failure Following Penetrating Keratoplasty in Patients at Increased Immunological Risk, 2007.
Alcon, Identification of Potential Inflammatory Markers on the Conjunctival Surface of Dry Eyed Individuals, 2007.
Sight Society of Northeastern New York, “Identification of Potential Inflammatory Markers on the Conjunctival Surface of Individuals with Dry Eye, 2007.
Alcon, Phase III, Safety and Efficacy of FID #109980 in the Treatment of Dry Eye, 2006.
Bausch and Lomb, Phase III, “Clinical and Microbial Efficacy of 0.6% ISV-403 compared to Vigamox in Bacterial Conjunctivitis,” 2006.
Sight Society of Northeastern New York, “Advanced Techniques in Anterior Segment Surgery,” 2006.
Sight Society of Northeastern New York, Evaluation of the Tear Film and Ocular Surface in Dry Eye Syndrome,” 2005.
Sight Society of Northeastern New York, “New Technology in the Objective Evaluation of Dry Eye Syndrome,” 2004.
Allergan, Phase II Study, Topical Testosterone (0.01%, 0.03%, and 0.1%) in Subjects with Meibomian Gland Dysfunction, 2003.
Alcon, Phase III Study, A Comparison of Ciprodex Ophthalmic Suspension, versus Ciloxan, Maxidex, and Ciprodex Vehicle for Treatment of Bacterial Blepharitis, 2003.
Sucampo Pharmaceuticals, Phase III Study, Efficacy and Safety of FK506 for Allergic Conjunctivitis, 2002.
Allergan, Phase III Study, Topical Cyclosporine for Dry Eye, 2001- 2002.
Sight Society of Northeastern NY, “Specular Microscopy in Corneal Graft Donor Viability,” 2000.
Cornea Donor Study, Jaeb Center for Health Research, 2000-10.
Maverick Technologies, Biomask Phototherapeutic Keratectomy (PTK) Study, 1998-1999.
VISX, Hyperopia with Refractive Astigmatism, Phase III Study, 1998-2000.
Sight Society of Northeastern NY, “Immunologic Mechanisms of Corneal Transplant Rejection,” 1998.